### NASH (Nonalcoholic Steatohepatitis) Patients

**Treatment Drug:**

Selonsertib

### INCLUSION Criteria: (Patient should meet the Inclusion criteria mentioned below to be eligible to participate)

1. Age 18-70
2. Liver biopsy consistent with NASH (defined as the presence of at least grade 1 steatosis, hepatocellular ballooning and lobular inflammation according to the NAFLD Activity score [NAS] and cirrhosis (F4Cirrhosis) according to the NASH CRN classification, in the opinion of the central reader.  
   a) A historical liver biopsy within 12 months of the screening visit may be accepted as the Screening biopsy if the sample is deemed acceptable for interpretation by the central reader.  
   b) If the subject is deemed ineligible for this study, the liver biopsy, if performed according to protocol specifications and is within 6 months of the Screening visit, may be used to determine eligible for study GS-US-384-1944.  
3. Subject has the following laboratory parameters at the Screening visit, as determined by the central laboratory:  
   a) ALT < 8 X uL  
   b) CLcr > 30 ml/min.  
   c) HbA1c < 9.5%  
4. Body Mass Index (BMI) > 18 kg/m at the Screening

ALL THE BELOW MENTIONED TESTS WILL BE FREE OF COST.  
(If the patient meets the inclusion criteria)

<table>
<thead>
<tr>
<th>STEP-1</th>
<th>Liver biopsy, Ultrasound Elastography</th>
<th>Patient has cirrhosis/Fibrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>STEP-2</td>
<td>ECG</td>
<td>ECG Should be Normal</td>
</tr>
<tr>
<td>STEP-3</td>
<td>HEMATOLOGY/BIOCHEMISTRY</td>
<td>CBP, HB, Serum electrolytes, Glucose, Albumin – Normal Valves</td>
</tr>
</tbody>
</table>
**Duration of the study:** Five Years

**No of Visits to the Hospital:** Once in a month (02 Screening visits+01 year-12 visits for Medication 02 year-04 visits +03year-04visits +04 year-04 visits+05 year-04 visits) **Total-30 visits.**

**Travelling amount per visit:** Rs 1200.